BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 31189677)

  • 1. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study.
    Chen Q; Ayer T; Bethea E; Kanwal F; Wang X; Roberts M; Zhuo Y; Fagiuoli S; Petersen J; Chhatwal J
    BMJ Open; 2019 Jun; 9(6):e026726. PubMed ID: 31189677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA.
    Chhatwal J; Chen Q; Ayer T; Bethea ED; Kanwal F; Kowdley KV; Wang X; Roberts MS; Gordon SC
    Aliment Pharmacol Ther; 2018 Apr; 47(7):1023-1031. PubMed ID: 29377245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?
    Pradat P; Pugliese P; Poizot-Martin I; Valantin MA; Cuzin L; Reynes J; Billaud E; Huleux T; Bani-Sadr F; Rey D; Frésard A; Jacomet C; Duvivier C; Cheret A; Hustache-Mathieu L; Hoen B; Cabié A; Cotte L;
    J Infect; 2017 Sep; 75(3):234-241. PubMed ID: 28579302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.
    Heffernan A; Cooke GS; Nayagam S; Thursz M; Hallett TB
    Lancet; 2019 Mar; 393(10178):1319-1329. PubMed ID: 30704789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort.
    Benhammou JN; Dong TS; May FP; Kawamoto J; Dixit R; Jackson S; Dixit V; Bhattacharya D; Han SB; Pisegna JR
    Pharmacol Res Perspect; 2018 Apr; 6(2):e00379. PubMed ID: 29484189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
    Mansour M; Hill L; Kerr J
    Transpl Infect Dis; 2018 Dec; 20(6):e12972. PubMed ID: 30080955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct acting antivirals failure: cause and retreatment options.
    Parlati L; Pol S
    Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1245-1250. PubMed ID: 30791789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of hepatitis C antiviral treatment and feasibility of hepatitis C elimination goal.
    Burgui C; San Miguel R; Goñi-Esarte S; Juanbeltz R; Úriz-Otano JI; Reparaz J; Sarobe M; Zozaya JM; Castilla J
    Postgrad Med; 2023 May; 135(4):352-360. PubMed ID: 36305320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained Virologic Response of Patients Hospitalized Compared With Those Not Hospitalized During Treatment for Hepatitis C Virus With Direct-Acting Antivirals.
    Gentene AJ; Bell AM; Pence A; Thomas K; Jakubecz C; Stacy E; Woolf B; Guido MR; Mueller EW; Sherman KE
    Ann Pharmacother; 2021 May; 55(5):565-574. PubMed ID: 33016095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.
    Martin NK; Vickerman P; Brew IF; Williamson J; Miners A; Irving WL; Saksena S; Hutchinson SJ; Mandal S; O'Moore E; Hickman M
    Hepatology; 2016 Jun; 63(6):1796-808. PubMed ID: 26864802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress towards hepatitis C virus elimination in high-income countries: An updated analysis.
    Gamkrelidze I; Pawlotsky JM; Lazarus JV; Feld JJ; Zeuzem S; Bao Y; Gabriela Pires Dos Santos A; Sanchez Gonzalez Y; Razavi H
    Liver Int; 2021 Mar; 41(3):456-463. PubMed ID: 33389788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in "special populations".
    Pol S; Parlati L
    Liver Int; 2018 Feb; 38 Suppl 1():28-33. PubMed ID: 29427485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of test-and-treat model with direct-acting antiviral for hepatitis C virus infection in migrants: a prospective interventional study in Italy.
    Coppola N; Alessio L; De Pascalis S; Macera M; Di Caprio G; Messina V; Onorato L; Minichini C; Stanzione M; Stornaiuolo G; Starace M; Monari C; Calò F; Sagnelli C; Pisaturo M
    Infect Dis Poverty; 2024 May; 13(1):39. PubMed ID: 38802954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: a modeling analysis.
    Skaathun B; Borquez A; Rivero-Juarez A; Mehta SR; Tellez F; Castaño-Carracedo M; Merino D; Palacios R; Macías J; Rivero A; Martin NK
    BMC Infect Dis; 2020 Aug; 20(1):588. PubMed ID: 32770955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global timing of hepatitis C virus elimination in high-income countries.
    Razavi H; Sanchez Gonzalez Y; Yuen C; Cornberg M
    Liver Int; 2020 Mar; 40(3):522-529. PubMed ID: 31815353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality.
    Wang Y; Rao H; Chi X; Li B; Liu H; Wu L; Zhang H; Liu S; Zhou G; Li N; Niu J; Wei L; Zhao J
    EBioMedicine; 2019 Aug; 46():227-235. PubMed ID: 31345785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?
    Kondili LA; Blach S; Razavi H; Craxì A
    Ann Ist Super Sanita; 2020; 56(3):325-329. PubMed ID: 32959798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
    Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
    Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.